Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study

Kobashi, Yurie; Nishikawa, Yoshitaka; Kawamura, Takeshi; Kodama, Tatsuhiko; Shimazu, Yuzo; Obara, Daiji; Zhao, Tianchen; Tsubokura, Masaharu

doi:10.1016/j.intimp.2021.107884

Cited by 18 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The age and sex distributions of the participants are shown in Fig 1C , and the sample characteristics and information on adverse vaccine events stratified by age are provided in Extended Data Table 1 . A portion of this cohort was described previously for the time period extending to 6 months after the first dose of mRNA vaccine 23, 24 .…”

Section: Resultsmentioning

confidence: 99%

Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Nakamura

Kobashi

Kim

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Recent studies have provided insights into the effect of vaccine boosters on recall immunity. Given the limited global supply of COVID-19 vaccines, identifying vulnerable populations with lower sustained vaccine-elicited antibody titers is important for targeting individuals for booster vaccinations. Here we investigated longitudinal data in a cohort of 2,526 people in Fukushima, Japan, from April 2021 to December 2021. Antibody titers following two doses of a COVID-19 vaccine were repeatedly monitored and information on lifestyle habits, comorbidities, adverse reactions, and medication use was collected. Using mathematical modeling and machine learning, we stratified the time-course patterns of antibody titers and identified vulnerable populations with low sustained antibody titers. Moreover, we showed that only 5.7% of the participants in our cohort were part of the "durable" population with high sustained antibody titers, which suggests that this durable population might be overlooked in small cohorts. We also found large variation in antibody waning within our cohort. There is a potential usefulness of our approach for identifying the neglected vulnerable population.

show abstract

Section: Resultsmentioning

confidence: 99%

Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Nakamura

Kobashi

Kim

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Fukushima Prefecture, 5.1% of the total population completed the third dose as of February 3, 2022 [13]. In addition, certain disaster-affected populations in Fukushima have been continuously subjected to COVID-19 antibody titers monitoring to develop infection prevention measures accordingly [14,15]. This area has an advantage in that the residents are aware of the level of their own liquid immunity after vaccination and how it has evolved, allowing assessment on how this affects their third vaccination behavior.…”

Section: Introductionmentioning

confidence: 99%

Factors Associated with COVID-19 Vaccine Booster Hesitancy: a Retrospective Cohort Study, Fukushima Vaccination Community Survey

Yoshida¹,

Kobashi²,

Kawamura³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

This was a retrospective cohort study, which aimed to investigate the factors associated with hesitancy to receive the third dose of coronavirus disease 2019 (COVID-19) vaccine. A paper-based questionnaire survey was administered to all participants. Accordingly, the study included participants who provided answer in the questionnaire whether they have an intent to receive the third dose of vaccine. Data on sex, age, area of residence, adverse reactions after the second vaccination, whether the third vaccination was desired, and reasons to accept or hesitate booster vaccination were retrieved. Among the 2439 participants with mean (±SD) age of 52.6±18.9 years, and median IgG-S antibody titer of 324.9 (AU/mL), 97.9% of participants indicated their intent to accept a third vaccination dose. The logistic regression revealed that younger age (OR=0.98; 95% CI: 0.96-1.00) and higher antibody level (OR=2.52; 95% CI: 1.27-4.99) are positively associated with the third vaccine hesitancy. The efficacy of the COVID-19 vaccine and concerns about adverse reactions had significant impact on the third vaccination behavior. A rapid increase in the booster dose rate is needed to control the pandemic, and specific approaches should be taken in these groups that are likely to hesitate the third vaccine, subsequently increasing booster contact rate.

show abstract

“…Written informed consent was obtained from all participants individually before the survey. A portion of this cohort was described previously for the period extending to 6 months after the first dose of mRNA vaccine (46, 47).…”

Section: Methodsmentioning

confidence: 99%

A personalized antibody score for predicting individual COVID-19 vaccine-elicited antibody levels from basic demographic and health information

Nakamura

Park

Kim

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Antibody titers wane after two-dose COVID-19 vaccinations, but individual variation in vaccine-elicited antibody dynamics remains to be explored. Here, we created a personalized antibody score that enables individuals to infer their antibody status by use of a simple calculation. We recently developed a mathematical model of B cell differentiation to accurately interpolate the longitudinal data from a community-based cohort in Fukushima, Japan, which consists of 2,159 individuals who underwent serum sampling two or three times after a two-dose vaccination with either BNT162b2 or mRNA-1273. Using the individually reconstructed time course of the vaccine-elicited antibody response, we first elucidated individual background factors that contributed to the main features of antibody dynamics, i.e., the peak, the duration, and the area under the curve. We found that increasing age was a negative factor and a longer interval between the two doses was a positive factor for individual antibody level. We also found that the presence of underlying disease and the use of medication affected antibody levels negatively, whereas the presence of adverse reactions upon vaccination affected antibody levels positively. We then applied to these factors a recently proposed computational method to optimally fit clinical scores, which resulted in an integer-based score that can be used to evaluate the antibody status of individuals from their basic demographic and health information. This score can be easily calculated by individuals themselves or by medical practitioners. There is a potential usefulness of this score for identifying vulnerable populations and encouraging them to get booster vaccinations.Significance statementDifferent individuals show different antibody titers even after the same COVID-19 vaccinations, making some individuals more prone to breakthrough infections than others. Such variability remains to be clarified. Here we used mathematical modeling to reconstruct individual post-vaccination antibody dynamics from a cohort of 2,159 individuals in Fukushima, Japan. Machine learning identified several positive and negative factors affecting individual antibody titers. Positive factors included adverse reactions after vaccinations and a longer interval between two vaccinations. Negative factors included age, underlying medical conditions, and medications. We combined these factors and developed an “antibody score” to estimate individual antibody dynamics from basic demographic and health information. This score can help to guide individual decision-making about taking further precautions against COVID-19.

show abstract

Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study

Cited by 18 publications

References 23 publications

Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Factors Associated with COVID-19 Vaccine Booster Hesitancy: a Retrospective Cohort Study, Fukushima Vaccination Community Survey

A personalized antibody score for predicting individual COVID-19 vaccine-elicited antibody levels from basic demographic and health information

Contact Info

Product

Resources

About